These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 18419402

  • 21. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
    Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.
    Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
    Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC, ZOE-70 Study Group.
    N Engl J Med; 2016 Sep 15; 375(11):1019-32. PubMed ID: 27626517
    [Abstract] [Full Text] [Related]

  • 23. Relationships of varicella zoster virus (VZV)-specific cell-mediated immunity and persistence of VZV DNA in saliva and the development of postherpetic neuralgia in patients with herpes zoster.
    Park SY, Kim JY, Kwon JS, Jeon NY, Kim MC, Chong YP, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH.
    J Med Virol; 2019 Nov 15; 91(11):1995-2000. PubMed ID: 31286531
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Herpes zoster subunit vaccine for the prevention of herpes zoster.
    Symoniak MR, Farrokh P, Gandhi MA, Slish JC.
    Am J Health Syst Pharm; 2018 Jun 15; 75(12):861-869. PubMed ID: 29880523
    [Abstract] [Full Text] [Related]

  • 28. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.
    Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A, Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators.
    J Infect Dis; 2008 Mar 15; 197(6):825-35. PubMed ID: 18419349
    [Abstract] [Full Text] [Related]

  • 29. Cost effectiveness of herpes zoster vaccine in Canada.
    Najafzadeh M, Marra CA, Galanis E, Patrick DM.
    Pharmacoeconomics; 2009 Mar 15; 27(12):991-1004. PubMed ID: 19908924
    [Abstract] [Full Text] [Related]

  • 30. Vaccine profile of herpes zoster (HZ/su) subunit vaccine.
    Cunningham AL, Heineman T.
    Expert Rev Vaccines; 2017 Jul 15; 16(7):1-10. PubMed ID: 28486850
    [Abstract] [Full Text] [Related]

  • 31. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
    van Oorschot DAM, Hunjan M, Bracke B, Lorenc S, Curran D, Starkie-Camejo H.
    BMJ Open; 2019 May 05; 9(5):e025553. PubMed ID: 31061027
    [Abstract] [Full Text] [Related]

  • 32. Prevention strategies for herpes zoster and post-herpetic neuralgia.
    Levin MJ, Gershon AA, Dworkin RH, Brisson M, Stanberry L.
    J Clin Virol; 2010 May 05; 48 Suppl 1(Suppl 1):S14-9. PubMed ID: 20510262
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R, Gomez JA, de Veras B, Pinto T, Guzman-Holst A, Nieto J, van Oorschot DAM.
    Hum Vaccin Immunother; 2023 Dec 31; 19(1):2164144. PubMed ID: 36821856
    [Abstract] [Full Text] [Related]

  • 37. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.
    Schmader K, Gnann JW, Watson CP.
    J Infect Dis; 2008 Mar 01; 197 Suppl 2():S207-15. PubMed ID: 18419399
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2213-2221. PubMed ID: 28708959
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.